text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 106308-44-5 | Product Number: R0143


Purity: >98.0%(HPLC)
  • 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
1   ≥20 
1   17  
Contact Us 12  

*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Product Number R0143
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__1__0H__8F__2N__4O = 238.20  
Physical State (20 deg.C) Solid
CAS RN 106308-44-5
Reaxys Registry Number 13495800
PubChem Substance ID 253662493
Merck Index (14) 8293
MDL Number


Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Elemental analysis(Nitrogen) 22.50 to 24.50 %
Melting point 239.0 to 243.0 °C
Properties (reference)
Melting Point 241 °C
Solubility in water Insoluble
Solubility (very slightly) Methanol,Tetrahydrofuran
Solubility (insoluble in) Ethanol
Pictogram Pictogram
Signal Word Warning
Hazard Statements H336 : May cause drowsiness or dizziness.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P261 : Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray.
P271 : Use only outdoors or in a well-ventilated area.
P304 + P340 + P312 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.
P403 + P233 : Store in a well-ventilated place. Keep container tightly closed.
P405 : Store locked up.
Related Laws:
Transport Information:
Rufinamide: A Broad-Spectrum Anticonvulsant Agent

Rufinamide is an antiepileptic agent with a triazole derivative structure. It is showed broad-spectrum anticonvulsant properties at nontoxic doses in animal models. The principal mechanism of action of rufinamide is considered to be the modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide is extensively metabolized in the liver by non-CYP450 enzymes. Recently, rufinamide is in development for the adjunctive treatment of refractory epilepsy, Lennox-Gastaut syndrome (LGS). (The product is for research purpose only.)


PubMed Literature

Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents